US moves closer to allowing emergency use of peramivir for H1N1
This article was originally published in Scrip
Executive Summary
The US government has moved a step closer to authorising emergency use of BioCryst Pharmaceuticals' investigational neuraminidase inhibitor peramivir for treating the new 2009 H1N1 influenza.